A new technique developed for the estimation of the absorbed dose prior to treatment with Sr-89 is presented. This technique implies that patient undergoes bone scanning with Tc-99m-MDP, two days before the administration of Sr-89. A number of sequential quantitative images are to be obtained over the first 8 hours after the Tc-99m-MDP injection and data are used to derive St-89 time retention curve. For the development of this technique a simplified model for the kinetics of both Sr-89 and Tc-99m-MDP was assumed. Data on the time retention of the two radiopharmaceuticals for a compartment including bone surface and bone space of trabecular and cortical bone for normal adults were combined together. A linear relationship was derived between the time required for the same percentage uptake of the two radiopharmaceuticals after single injection. The absorbed dose in the principal metastases and normal bone, of the same type and volume with the metastases, for two patients who were treated with Sr-89 for metastasized prostatic carcinoma are reported. (authors). 23 refs,3 figs, 2 tabs.